Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies

• DOI: 10.1093/europace/euae076
• Publication Date: 2024-04-07T06:06:07Z
• Authors: Atul Verma; Vidal Essebag; Petr Neuzil; Katia Dyrda; Jippe Balt; Borislav Dinov; Angeliki Darma; Arash Arya; Frederic Sacher; Vivek Y Reddy; Lucas Boersma; Ilya Grigorov; Tom De Potter
• Keywords: Cryoablation; Clinical endpoint; Cryosurgery

The ultra-low-temperature cryoablation (ULTC) ablation system using -196°C N2 cryogen has been reported to create lesions with freeze duration-dependent depth titratable over 10 mm minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of novel, purpose-built ULTC catheter in endocardial scar-dependent ventricular tachycardias (VTs).